Prostate cancer: measuring PSA

Population screening with prostate‐specific antigen (PSA) for detection of prostate cancer is a topic associated with ongoing dissent and confusion within the oncology and wider medical community. The PSA blood test has been used in various stages of prostate cancer management, including screening a...

Full description

Saved in:
Bibliographic Details
Published in:Internal medicine journal 2014-05, Vol.44 (5), p.433-440
Main Authors: Pezaro, C., Woo, H. H., Davis, I. D.
Format: Article
Language:English
Subjects:
Adenocarcinoma - blood
Adenocarcinoma - diagnosis
Adenocarcinoma - epidemiology
Adenocarcinoma - secondary
Antigens, Neoplasm - urine
Australasia - epidemiology
Clinical Trials as Topic
Decision Support Techniques
Early Detection of Cancer - methods
Early Detection of Cancer - statistics & numerical data
Humans
Male
monitoring
Multicenter Studies as Topic
Neoplasm Grading
Neoplasm Metastasis
Neoplasm Recurrence, Local - blood
Neoplasm Staging
Practice Guidelines as Topic
Predictive Value of Tests
prostate cancer
prostate-specific antigen (PSA)
Prostate-Specific Antigen - blood
Prostatic Neoplasms - blood
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - epidemiology
Prostatic Neoplasms - pathology
Prostatic Neoplasms - therapy
Randomized Controlled Trials as Topic
Reference Values
Risk Assessment
screening
Survival Analysis
Unnecessary Procedures
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Population screening with prostate‐specific antigen (PSA) for detection of prostate cancer is a topic associated with ongoing dissent and confusion within the oncology and wider medical community. The PSA blood test has been used in various stages of prostate cancer management, including screening and the assessment of future risk of prostate cancer development, detection of recurrent disease after local therapy and in the management of advanced disease. However, PSA‐based decision‐making in prostate cancer has significant shortcomings. This review will summarise the evidence and current recommendations for the use of PSA in detection and management of prostate cancer.
ISSN:1444-0903
1445-5994
DOI:10.1111/imj.12407